J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Colburn, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Colburn, W.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development

WA Colburn

Biomarkers and surrogate endpoints are critical to the future of efficient drug development. Definitions, a conceptual model, and a conceptual framework for validating and bridging biomarkers to clinical endpoints are provided in this presentation. In addition, a few examples are provided to support the development concept. Poor correlation between a biomarker and its clinical endpoint may result from (1) poor measurement of one or both, (2) selection of an inappropriate biomarker, or, more important, (3) use of an inappropriate clinical endpoint. Pharmacokinetic/pharmacodynamic (PK/PD) modeling output can be no better than biomarkers or surrogate endpoints used for the modeling. As we increase our understanding of biomarkers, surrogate markers, and the mechanistic basis for the processes of interest, biomarker and surrogate endpoint predictive power will no longer be an issue and PK/PD modeling inputs and outputs will improve.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Postgrad. Med. J.Home page
V O Puntmann
How-to guide on biomarkers: biomarker definitions, validation and applications with examples from cardiovascular disease
Postgrad. Med. J., October 1, 2009; 85(1008): 538 - 545.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
R. S. Vasan
Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations
Circulation, May 16, 2006; 113(19): 2335 - 2362.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
D. R. H. Huntjens, M. Danhof, and O. E. Della Pasqua
Pharmacokinetic pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors
Rheumatology, July 1, 2005; 44(7): 846 - 859.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
E. M. Fach, L.-A. Garulacan, J. Gao, Q. Xiao, S. M. Storm, Y. P. Dubaquie, S. A. Hefta, and G. J. Opiteck
In Vitro Biomarker Discovery for Atherosclerosis by Proteomics
Mol. Cell. Proteomics, December 1, 2004; 3(12): 1200 - 1210.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
G R Laking and P M Price
Positron emission tomographic imaging of angiogenesis and vascular function
Br. J. Radiol., December 1, 2003; 76(suppl_1): S50 - S59.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
W. A. Colburn
Biomarkers in Drug Discovery and Development: From Target Identification through Drug Marketing
J. Clin. Pharmacol., April 1, 2003; 43(4): 329 - 341.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American College of Clinical Pharmacology